Literature DB >> 30537018

Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.

Sara Blanco-Dorado1,2, Ana Teresa Marques Afonso3, Enrique José Bandín-Vilar1,2, Ignacio Novo-Veleiro3, Fernando Ferrón Vidán3, Ana Latorre-Pellicer4,5, Olalla Maroñas Amigo4,5, Anxo Fernández-Ferreiro1,2,6, María Jesús Lamas2.   

Abstract

Entities:  

Keywords:  glucocorticoid; pharmacokinetic interaction; voriconazole

Mesh：

Substances：

Year:  2018        PMID： 30537018      PMCID： PMC6339966          DOI： 10.1111/bcp.13819

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  23 in total

1.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

Review 2.  Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.

Authors:  Petra Matoulková; Petr Pávek; Josef Malý; Jiří Vlček
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-01-23       Impact factor: 4.481

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

4.  Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.

Authors:  Sara Blanco-Dorado; Ana Teresa Marques Afonso; Enrique José Bandín-Vilar; Ignacio Novo-Veleiro; Fernando Ferrón Vidán; Ana Latorre-Pellicer; Olalla Maroñas Amigo; Anxo Fernández-Ferreiro; María Jesús Lamas
Journal:  Br J Clin Pharmacol       Date:  2018-12-09       Impact factor: 4.335

Review 5.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

7.  Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Authors:  Sauzanne Khalilieh; Azher Hussain; Diana Montgomery; Vanessa Levine; Peter M Shaw; Inga Bodrug; Lally Mekokishvili; Candice Bailey-Smith; Xiaoli S Glasgow; Amy Cheng; Monika Martinho; Marian Iwamoto
Journal:  Br J Clin Pharmacol       Date:  2018-07-31       Impact factor: 4.335

Review 8.  Case definition and phenotype standardization in drug-induced liver injury.

Authors:  G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

9.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 10.  Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.

Authors:  Haiying Jin; Tiansheng Wang; Bonnie A Falcione; Keith M Olsen; Ken Chen; Huilin Tang; John Hui; Suodi Zhai
Journal:  J Antimicrob Chemother       Date:  2016-03-10       Impact factor: 5.790
View more
  2 in total

1.  Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.

Authors:  Sara Blanco-Dorado; Ana Teresa Marques Afonso; Enrique José Bandín-Vilar; Ignacio Novo-Veleiro; Fernando Ferrón Vidán; Ana Latorre-Pellicer; Olalla Maroñas Amigo; Anxo Fernández-Ferreiro; María Jesús Lamas
Journal:  Br J Clin Pharmacol       Date:  2018-12-09       Impact factor: 4.335

2.  A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.

Authors:  Sara Blanco Dorado; Olalla Maroñas Amigo; Ana Latorre-Pellicer; María Teresa Rodríguez Jato; Ana López-Vizcaíno; Aurea Gómez Márquez; Belén Bardán García; Dolores Belles Medall; Gema Barbeito Castiñeiras; María Luisa Pérez Del Molino Bernal; Manuel Campos-Toimil; Francisco Otero Espinar; Andrés Blanco Hortas; Irene Zarra Ferro; Ángel Carracedo; María Jesús Lamas; Anxo Fernández-Ferreiro
Journal:  Br J Clin Pharmacol       Date:  2020-03-09       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.